| pubmed-article:16478630 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16478630 | lifeskim:mentions | umls-concept:C0302592 | lld:lifeskim |
| pubmed-article:16478630 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:16478630 | lifeskim:mentions | umls-concept:C1512288 | lld:lifeskim |
| pubmed-article:16478630 | lifeskim:mentions | umls-concept:C0007137 | lld:lifeskim |
| pubmed-article:16478630 | lifeskim:mentions | umls-concept:C1522690 | lld:lifeskim |
| pubmed-article:16478630 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:16478630 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:16478630 | lifeskim:mentions | umls-concept:C0279284 | lld:lifeskim |
| pubmed-article:16478630 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:16478630 | pubmed:dateCreated | 2006-7-18 | lld:pubmed |
| pubmed-article:16478630 | pubmed:abstractText | Doxorubicin has reported activity in advanced and recurrent cervical cancer but hematologic toxicity has limited its use in some combinations. To determine the level of activity and potential for use in future combinations, a phase II trial of pegylated liposomal doxorubicin as second-line therapy in advanced and recurrent cervical cancer was performed. | lld:pubmed |
| pubmed-article:16478630 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16478630 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16478630 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16478630 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16478630 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16478630 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16478630 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16478630 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16478630 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16478630 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16478630 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:16478630 | pubmed:issn | 0090-8258 | lld:pubmed |
| pubmed-article:16478630 | pubmed:author | pubmed-author:BlessingJohn... | lld:pubmed |
| pubmed-article:16478630 | pubmed:author | pubmed-author:RosePeter GPG | lld:pubmed |
| pubmed-article:16478630 | pubmed:author | pubmed-author:LeleShashikan... | lld:pubmed |
| pubmed-article:16478630 | pubmed:author | pubmed-author:AbulafiaOvadi... | lld:pubmed |
| pubmed-article:16478630 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16478630 | pubmed:volume | 102 | lld:pubmed |
| pubmed-article:16478630 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16478630 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16478630 | pubmed:pagination | 210-3 | lld:pubmed |
| pubmed-article:16478630 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:16478630 | pubmed:meshHeading | pubmed-meshheading:16478630... | lld:pubmed |
| pubmed-article:16478630 | pubmed:meshHeading | pubmed-meshheading:16478630... | lld:pubmed |
| pubmed-article:16478630 | pubmed:meshHeading | pubmed-meshheading:16478630... | lld:pubmed |
| pubmed-article:16478630 | pubmed:meshHeading | pubmed-meshheading:16478630... | lld:pubmed |
| pubmed-article:16478630 | pubmed:meshHeading | pubmed-meshheading:16478630... | lld:pubmed |
| pubmed-article:16478630 | pubmed:meshHeading | pubmed-meshheading:16478630... | lld:pubmed |
| pubmed-article:16478630 | pubmed:meshHeading | pubmed-meshheading:16478630... | lld:pubmed |
| pubmed-article:16478630 | pubmed:meshHeading | pubmed-meshheading:16478630... | lld:pubmed |
| pubmed-article:16478630 | pubmed:meshHeading | pubmed-meshheading:16478630... | lld:pubmed |
| pubmed-article:16478630 | pubmed:meshHeading | pubmed-meshheading:16478630... | lld:pubmed |
| pubmed-article:16478630 | pubmed:meshHeading | pubmed-meshheading:16478630... | lld:pubmed |
| pubmed-article:16478630 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16478630 | pubmed:articleTitle | Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. | lld:pubmed |
| pubmed-article:16478630 | pubmed:affiliation | Division of Gynecologic Oncology, Case Western Reserve University, Cleveland, OH 44106, USA. rosep@ccf.org | lld:pubmed |
| pubmed-article:16478630 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16478630 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:16478630 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| pubmed-article:16478630 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
